Novel Treatment Approaches with mAbs Targeting Amyloid Deposits: Insights from VITAL
Source: OncLive, February 2024
A panel of expert oncologists explore novel therapies using monoclonal antibodies designed to target amyloid deposit, highlighting key data from the VITAL study.
This is a video synopsis/summary of a Peer Exchange involving Heather Landau, MD; Vaishali Sanchorawala, MD; and Jeffrey Zonder, MD.
The discussion focuses on promising developments in amyloidosis treatment, particularly the amyloid-busting agents. Two notable monoclonal antibodies (mAbs) in advanced development are highlighted: CAEL-101 and birtamimab. CAEL-101 targets the end terminus of kappa and lambda light chains, attaching to amyloid fibril deposits in phase 3 trials involving stage 3A and 3B patients. The results, expected in 2024, hold promise for advancing amyloidosis treatment. Birtamimab, directed at the C terminus of kappa and lambda light chains, dissolves amyloid deposits and soluble oligomers. Despite the VITAL study being halted for futility analysis, post hoc analysis revealed a favorable all-cause mortality outcome at 9 months for birtamimab in combination with standard care treatment. These antifibrillar antibodies represent innovative approaches in the evolving landscape of amyloidosis therapeutics.